BridgeBio Pharma CFO Sells $2.1mln Worth of Stock Amidst Q2 Earnings Success

BridgeBio Pharma's President and CFO Thomas Trimarchi sold 42,237 shares of stock on August 22, 2025, worth $2.09 million. The company reported strong Q2 earnings, driven by the successful launch of Attruby, which achieved $71.5 million in net product revenue. Analysts have adjusted their price targets upward, reflecting BridgeBio's growth momentum and upcoming Phase III readouts. However, a slight post-market share dip occurred due to Attruby's sales missing expectations.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) has seen significant insider trading activity and reported strong quarterly earnings. On August 22, 2025, the company's President and CFO, Thomas Trimarchi, sold 42,237 shares of stock, totaling $2.09 million [1]. This transaction follows a series of sales by the company's top executives, including CEO Neil Kumar, who sold shares worth $1.27 million on August 20, 2025 [1].

The sales come as BridgeBio Pharma reported its second-quarter 2025 earnings, revealing a significant revenue increase. The company achieved a revenue of $110.6 million, which exceeded the forecast of $99.72 million by 10.87% [2]. The earnings per share fell short of expectations, with a loss of $0.95 compared to the anticipated loss of $0.75. Attruby sales played a crucial role, with sales doubling in the second full quarter of availability, as noted by TD Cowen [2]. The firm reiterated its Buy rating and maintained a $60.00 price target on BridgeBio Pharma due to this strong performance.

Analysts have adjusted their price targets upward, reflecting BridgeBio's growth momentum and upcoming Phase III readouts. BridgeBio Pharma has earned 19 "Buy" ratings from Wall Street analysts, with a 17.15% average price target upside to $60.12 [4]. Despite the strong earnings, a slight post-market share dip occurred due to Attruby's sales missing expectations.

These developments highlight the company's ongoing momentum in its sales performance and position it as a high-conviction biotech growth opportunity. BridgeBio Pharma's financial position, with $756.9 million in cash reserves, further bolsters its investment case [4]. The company is poised to deliver strong returns and break even in the near future, supported by its strategic flexibility and operational execution.

References:
[1] https://www.tradingview.com/news/tradingview:24ce6b70ceaf6:0-bridgebio-pharma-ceo-neil-kumar-sells-shares/
[2] https://ng.investing.com/news/insider-trading-news/bridgebio-pharma-bbio-president-sells-shares-worth-871k-93CH-2071750
[4] https://www.ainvest.com/news/bridgebio-pharma-bbio-poised-deliver-strong-returns-breakeven-gains-analyst-momentum-2508/